Skip to main content

Table 6 Multivariate analysis of LR, RR, and DM of young breast cancer patients

From: Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases

Characteristics LR RR DM
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Tumor size   < 0.01   0.11   0.01
T1 1.0   1.0   1.0  
T2 0.5 (0.2–1.0) 0.05 0.6 (0.3–1.4) 0.24 1.4 (0.9–2.3) 0.16
T3 1.7 (0.6– 4.8) 0.33 1.2 (0.5–2.9) 0.74 1.8 (1.0–3.2) 0.04
T4 6.5 (1.2–36.9) 0.03 4.2 (1.0–17.2) 0.05 5.4 (2.0–14.0) < 0.01
Stage   0.24   0.09   0.57
I 1.0   1.0   1.0  
II a 1.7 (0.7–4.2) 0.22 0.5 (0.2–1.6) 0.26 1.4 (0.7–2.8) 0.28
II b 2.1 (0.6–7.8) 0.25 2.2 (0.6–8.8) 0.25 1.3 (0.5–3.4) 0.53
III a 0.7 (0.2–3.5) 0.69 0.9 (0.2–4.4) 0.90 2.1 (0.8–5.8) 0.15
III b 0.9 (0.1–9.0) 0.96 0.3 (0.0–4.8) 0.43 1.2 (0.3–4.9) 0.81
III c 0.5 (0.1–3.6) 0.53 0.2 (0.0–1.5) 0.11 4.2 (1.0–17.8) 0.05
LN metastasis   0.06   0.02   0.59
N0 1.0   1.0   1.0  
N1 2.0 (1.0–4.0) 0.05 1.6 (0.6–4.1) 0.32 1.5 (0.9–2.6) 0.14
N2 1.01 (0.3–3.5) 0.93 7.1 (1.7–29.2) < 0.01 1.3 (0.6–2.9) 0.50
N3 6.9 (1.4–35.0) 0.02 34.7 (4.0–304.1) < 0.01 1.3 (0.3–4.7) 0.73
Final surgery   –   –   0.14
Mastectomy –   –   1.0  
BCS – – – – 0.7 (0.4–1.1) 0.14
ER status   0.70   –   –
Positive 1.0   –   –  
Negative 1.5 (0.6–3.9) 0.40 – – – –
PR status   0.54   –   –
Positive 1.0   –   –  
Negative 1.5 (0.6–3.6) 0.41 – – – –
HER2 status   0.92   –   –
Positive 1.0   –   –  
Negative 0.0 (0.0–NA) 0.92 – – – –
MS   0.49   –   0.01
HR+/HER2− 1.0   –   1.0  
HR+/HER2+ 0.0 (0.0–NA) 0.92 – – 1.4 (0.9–2.1) 0.15
HR−/HER2+ 0.0 (0.0–NA) 0.92 – – 2.5 (1.5–4.4) < 0.01
HR−/HER2− 0.3 (0.1–1.2) 0.10 – – 1.9 (1.1–3.2) 0.02
NACT   0.57   0.11   0.04
No 1.0   1.0   1.0  
Yes 1.2 (0.7–2.2) 0.57 1.6 (0.9–3.0) 0.11 1.4 (1.0–2.0) 0.04
Radiotherapy   –   0.10   0.64
No –   1.0   1.0  
Yes – – 0.5 (0.2–1.1) 0.09 1.2 (0.7–2.0) 0.41
ET   0.07   –   –
No 1.0   –   –  
Yes 0.4 (0.2–1.0) 0.04 – – – –
OFS   –   0.03   < 0.01
No –   1.0   1.0  
Yes – – 2.4 (1.2–4.6) < 0.01 3.7 (2.3–5.8) < 0.01
  1. UA, univariate analysis; MA, multivariate analysis; HG, histological grade; MS, molecular subtype; NACT, neoadjuvant chemotherapy; ACT, adjuvant chemotherapy; ET, endocrine therapy; TT, trastuzumab therapy; NA, not arrived
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us

\